IL80213A - Quinazoline derivatives,process for the preparation thereof and pharmaceutical compositions containing the same - Google Patents

Quinazoline derivatives,process for the preparation thereof and pharmaceutical compositions containing the same

Info

Publication number
IL80213A
IL80213A IL80213A IL8021386A IL80213A IL 80213 A IL80213 A IL 80213A IL 80213 A IL80213 A IL 80213A IL 8021386 A IL8021386 A IL 8021386A IL 80213 A IL80213 A IL 80213A
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
same
compositions containing
alkyl
Prior art date
Application number
IL80213A
Other languages
English (en)
Other versions
IL80213A0 (en
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of IL80213A0 publication Critical patent/IL80213A0/xx
Publication of IL80213A publication Critical patent/IL80213A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL80213A 1985-10-07 1986-10-02 Quinazoline derivatives,process for the preparation thereof and pharmaceutical compositions containing the same IL80213A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858524663A GB8524663D0 (en) 1985-10-07 1985-10-07 Quinazoline derivatives

Publications (2)

Publication Number Publication Date
IL80213A0 IL80213A0 (en) 1987-01-30
IL80213A true IL80213A (en) 1991-06-30

Family

ID=10586291

Family Applications (1)

Application Number Title Priority Date Filing Date
IL80213A IL80213A (en) 1985-10-07 1986-10-02 Quinazoline derivatives,process for the preparation thereof and pharmaceutical compositions containing the same

Country Status (23)

Country Link
US (2) US4734419A (de)
EP (1) EP0218999B1 (de)
JP (3) JPS6296476A (de)
KR (1) KR940007270B1 (de)
CN (1) CN1017242B (de)
AT (1) ATE60761T1 (de)
AU (1) AU596611B2 (de)
CA (1) CA1289139C (de)
DE (1) DE3677452D1 (de)
DK (1) DK158838C (de)
ES (1) ES2021266B3 (de)
FI (1) FI90234C (de)
GB (1) GB8524663D0 (de)
GR (1) GR3001502T3 (de)
HK (1) HK6993A (de)
HU (1) HU196972B (de)
IE (1) IE59309B1 (de)
IL (1) IL80213A (de)
NO (1) NO171785C (de)
SG (1) SG112092G (de)
SU (1) SU1588283A3 (de)
UA (1) UA5562A1 (de)
ZA (1) ZA867043B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
PH23853A (en) * 1986-08-21 1989-11-23 Pfizer Pyridopyrimidinediones
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
US4931440A (en) * 1987-07-29 1990-06-05 Fujisawa Pharmaceutical Company, Ltd. Uricosuric composition
WO1989002432A1 (en) * 1987-09-16 1989-03-23 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivatives
JP2621460B2 (ja) * 1988-02-29 1997-06-18 藤沢薬品工業株式会社 利尿または降圧剤
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
AU683620B2 (en) * 1992-09-28 1997-11-20 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
DE19532052C2 (de) * 1995-08-31 1998-11-19 Clariant Gmbh Verfahren zur Herstellung von Chinazolinderivaten
DE59606237D1 (de) * 1995-08-31 2001-01-25 Clariant Gmbh Monoester der carboxymethylenanthranilsäuren und verfahren zu ihrer herstellung
DE69614986T2 (de) * 1995-12-26 2002-04-25 Sumitomo Chemical Co Verfahren zur Herstellung von Isatosäureanhydriden
US6201121B1 (en) 1995-12-28 2001-03-13 Fuji Chemical Industry Co., Ltd. Process for the preparation of 3-dihalobenzyl-2,4-quinazolinedione derivatives
DE69701647T2 (de) * 1996-02-01 2000-09-07 Sumitomo Chemical Co Verfahren zur Herstellung von Dioxochinazolinen
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
WO1998046243A2 (en) * 1997-04-15 1998-10-22 Csir Pharmaceutical compositions having appetite suppressant activity
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
KR20010040457A (ko) * 1998-01-30 2001-05-15 우에노 류지 안약 조성물
WO2000043015A1 (fr) * 1999-01-25 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Gouttes ophtalmologiques
CA2328877A1 (en) 1999-02-18 2000-08-24 R-Tech Ueno, Ltd. Composition for treatment of external secretion disorders except hypolacrimation
EP1160243A4 (de) * 1999-03-09 2002-06-26 Fujisawa Pharmaceutical Co Verfahren zur herstellung von chinazolinderivaten oder ihren salzen
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
EP1337272A2 (de) 2000-11-30 2003-08-27 Pfizer Products Inc. Kombination von gaba agonisten und aldose reductase inhibitoren
WO2002098462A1 (fr) * 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation
CA2475879A1 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
US20040053948A1 (en) * 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003106426A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (de) * 2002-07-23 2008-04-16 Cytokinetics Inc Verbindungen, zusammenstellungen und verfahren
US20040048853A1 (en) * 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
EP1682534A2 (de) * 2003-11-03 2006-07-26 Cytokinetics, Inc. Pyrimidin-4-onverbindungen, zusammensetzungen und verfahren
EP1680420A4 (de) * 2003-11-07 2008-09-24 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1692112A4 (de) * 2003-12-08 2008-09-24 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
KR101433395B1 (ko) * 2006-07-19 2014-08-26 이 아이 듀폰 디 네모아 앤드 캄파니 3-치환된 2-아미노-5-할로벤즈아미드의 제조 방법
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
EP2848252A3 (de) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose-Reduktase-Inhibitoren zur Behandlung von Uveitis
WO2009019149A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN102219759B (zh) * 2010-04-16 2013-07-24 中国科学院上海药物研究所 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
CA2822672C (en) 2010-12-23 2018-06-05 The Board Of Regents Of The University Of Texas System Methods for treating copd
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994139B1 (de) 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc-hemmer und verwendungen davon
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
CN111499616B (zh) * 2020-05-07 2022-07-22 盐城工学院 一种芳杂环取代的喹唑啉酮衍生物及其合成方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016166A (en) * 1973-12-14 1977-04-05 Hisamitsu Pharmaceutical Co., Inc. 1-Nitrophenylquinazoline-2,4(1H,3H)-diones
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
CA1161036A (en) * 1980-05-15 1984-01-24 Masayuki Ishikawa Quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
EP0040793B1 (de) * 1980-05-22 1985-08-28 Masayuki Ishikawa Chinazolindion-Verbindungen, Verfahren zu deren Herstellung und deren pharmazeutische Verwendung
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
DD232702A1 (de) * 1982-09-20 1986-02-05 Adw Ddr Verfahren zur herstellung von 1,2,3,4-tetrahydrochinazolin-2,4-dion-essigsaeuren, deren salzen und estern
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
JPS59186963A (ja) * 1983-04-08 1984-10-23 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives

Also Published As

Publication number Publication date
US4734419A (en) 1988-03-29
KR870003998A (ko) 1987-05-06
EP0218999B1 (de) 1991-02-06
IE59309B1 (en) 1994-02-09
NO171785B (no) 1993-01-25
DK158838C (da) 1991-01-14
JPH01131164A (ja) 1989-05-24
DK459086A (da) 1987-04-08
ATE60761T1 (de) 1991-02-15
UA5562A1 (uk) 1994-12-28
JPH0794447B2 (ja) 1995-10-11
AU6358986A (en) 1987-04-09
FI863917A0 (fi) 1986-09-29
GB8524663D0 (en) 1985-11-13
DK158838B (da) 1990-07-23
DE3677452D1 (de) 1991-03-14
SG112092G (en) 1992-12-24
EP0218999A3 (en) 1988-01-13
EP0218999A2 (de) 1987-04-22
HUT41747A (en) 1987-05-28
JPH05366B2 (de) 1993-01-05
JPH0482148B2 (de) 1992-12-25
AU596611B2 (en) 1990-05-10
ZA867043B (en) 1987-07-29
NO171785C (no) 1993-05-05
IE862520L (en) 1987-04-07
JPH01125322A (ja) 1989-05-17
FI90234B (fi) 1993-09-30
IL80213A0 (en) 1987-01-30
CN86106984A (zh) 1987-05-20
ES2021266B3 (es) 1991-11-01
CA1289139C (en) 1991-09-17
HU196972B (en) 1989-02-28
DK459086D0 (da) 1986-09-25
NO863980L (no) 1987-04-08
JPS6296476A (ja) 1987-05-02
KR940007270B1 (en) 1994-08-12
NO863980D0 (no) 1986-10-06
GR3001502T3 (en) 1992-11-23
FI863917A (fi) 1987-04-08
SU1588283A3 (ru) 1990-08-23
FI90234C (fi) 1994-01-10
CN1017242B (zh) 1992-07-01
US4883800A (en) 1989-11-28
HK6993A (en) 1993-02-05

Similar Documents

Publication Publication Date Title
IL80213A0 (en) Quinazoline derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
IL107426A0 (en) Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same
IL109395A0 (en) Heterocyclic derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL74031A0 (en) Cyanoguanidinophenyldihydropyridazinone derivatives,their preparation and pharmaceutical compositions containing them
HUT56089A (en) Process for producing quinazoline derivatives and pharmaceutical compositions containing them
DK283984A (da) Benzodiazepinderivater og fremgangsmaade til fremstilling deraf
IL92010A0 (en) Pyrrolidine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
ZA872925B (en) Heterocyclic compounds

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees
HC Change of name of proprietor(s)